Literature DB >> 10721504

Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach.

A Caflisch1, H J Schramm, M Karplus.   

Abstract

Inhibition of dimerization to the active form of the HIV-1 aspartic proteinase (HIV-1 PR) may be a way to decrease the probability of escape mutations for this viral protein. The Multiple Copy Simultaneous Search (MCSS) methodology was used to generate functionality maps for the dimerization interface of HIV-1 PR. The positions of the MCSS minima of 19 organic fragments, once postprocessed to take into account solvation effects, are in good agreement with experimental data on peptides that bind to the interface. The MCSS minima combined with an approach for computational combinatorial ligand design yielded a set of modified HIV-1 PR C-terminal peptides that are similar to known nanomolar inhibitors of HIV-1 PR dimerization. A number of N-substituted 2,5-diketopiperazines are predicted to be potential dimerization inhibitors of HIV-1 PR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10721504     DOI: 10.1023/a:1008146201260

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  27 in total

1.  Complete mutagenesis of the HIV-1 protease.

Authors:  D D Loeb; R Swanstrom; L Everitt; M Manchester; S E Stamper; C A Hutchison
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

2.  HIV-1 reproduction is inhibited by peptides derived frm the N- and C-termini of HIV-1 protease.

Authors:  H J Schramm; H Nakashima; W Schramm; H Wakayama; N Yamamoto
Journal:  Biochem Biophys Res Commun       Date:  1991-09-16       Impact factor: 3.575

3.  Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide.

Authors:  Z Y Zhang; R A Poorman; L L Maggiora; R L Heinrikson; F J Kézdy
Journal:  J Biol Chem       Date:  1991-08-25       Impact factor: 5.157

4.  Functionality maps of binding sites: a multiple copy simultaneous search method.

Authors:  A Miranker; M Karplus
Journal:  Proteins       Date:  1991

5.  Computational screening of combinatorial libraries.

Authors:  Q Zheng; D J Kyle
Journal:  Bioorg Med Chem       Date:  1996-05       Impact factor: 3.641

6.  Functionality map analysis of the active site cleft of human thrombin.

Authors:  P D Grootenhuis; M Karplus
Journal:  J Comput Aided Mol Des       Date:  1996-02       Impact factor: 3.686

7.  Use of the multiple copy simultaneous search (MCSS) method to design a new class of picornavirus capsid binding drugs.

Authors:  D Joseph-McCarthy; J M Hogle; M Karplus
Journal:  Proteins       Date:  1997-09

Review 8.  Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

Authors:  R M Hoetelmans; P L Meenhorst; J W Mulder; D M Burger; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1997-08

9.  The inhibition of HIV-1 protease by interface peptides.

Authors:  H J Schramm; A Billich; E Jaeger; K P Rücknagel; G Arnold; W Schramm
Journal:  Biochem Biophys Res Commun       Date:  1993-07-30       Impact factor: 3.575

10.  Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

Authors:  H R Brodt; B S Kamps; P Gute; B Knupp; S Staszewski; E B Helm
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

View more
  5 in total

1.  Evaluation of designed ligands by a multiple screening method: application to glycogen phosphorylase inhibitors constructed with a variety of approaches.

Authors:  S S So; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2001-07       Impact factor: 3.686

2.  Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors.

Authors:  V Zoete; O Michielin; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

3.  Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

Authors:  David A Davis; Irene R Tebbs; Sarah I Daniels; Stephen J Stahl; Joshua D Kaufman; Paul Wingfield; Michael J Bowman; Jean Chmielewski; Robert Yarchoan
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

4.  Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.

Authors:  Gabriella Miklóssy; József Tözsér; János Kádas; Rieko Ishima; John M Louis; Péter Bagossi
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

5.  Targeting human immunodeficiency virus type 1 assembly, maturation and budding.

Authors:  Johanna Wapling; Seema Srivastava; Miranda Shehu-Xhilaga; Gilda Tachedjian
Journal:  Drug Target Insights       Date:  2007-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.